Medical Marijuana for Chronic Pain in New Jersey
Chronic pain is the most common reason patients come to PremierMD for a medical cannabis evaluation — and among all the qualifying conditions in the NJ program, it has the strongest evidence base. New Jersey lists chronic pain as one of its 18 approved qualifying conditions, and patients whose pain has not responded adequately to standard treatments have a clear pathway to a physician-certified evaluation billed to their insurance.
Does Chronic Pain Qualify for the NJ Medicinal Cannabis Program?
Yes. Chronic pain is a direct qualifying condition under the NJ Medicinal Cannabis Program. You do not need a secondary diagnosis to apply under this category. You do need documentation — a physician record showing a chronic pain diagnosis, not just a report of symptoms. Records from a primary care physician, pain management specialist, orthopedic surgeon, rheumatologist, or any licensed provider who has documented your chronic pain diagnosis are accepted at PremierMD.
If your chronic pain has been managed informally — without a physician visit resulting in a written diagnosis — PremierMD can evaluate and document the qualifying diagnosis as part of a primary care visit before or alongside the cannabis evaluation. See: Do I Qualify for a Medical Marijuana Card in New Jersey?
How Medical Cannabis Helps Chronic Pain
The human body's endocannabinoid system (ECS) plays a central role in pain regulation. CB1 receptors — found throughout the brain, spinal cord, and peripheral nerves — modulate pain signaling in the dorsal horn of the spinal cord, one of the primary relay points for pain signals traveling to the brain. CB2 receptors, concentrated in immune tissues and peripheral organs, modulate inflammatory responses that contribute to pain in conditions like arthritis, inflammatory bowel disease, and musculoskeletal injury.
Cannabis compounds interact directly with this system:
THC (tetrahydrocannabinol) binds primarily to CB1 receptors and reduces pain signal transmission in the central nervous system. At appropriate doses, it also acts on descending pain modulation pathways, which influence how strongly the brain processes incoming pain signals.
CBD (cannabidiol) has multiple mechanisms relevant to pain: it modulates the activity of anandamide (the body's naturally produced endocannabinoid), has anti-inflammatory effects via multiple pathways, and interacts with TRPV1 receptors involved in pain and temperature sensation.
Neuropathic pain (nerve damage pain, diabetic neuropathy, post-surgical nerve pain) tends to respond well to CBD-dominant and balanced products. Inflammatory pain (arthritis, inflammatory conditions) may respond better to combinations of CBD and THC. Musculoskeletal pain can sometimes be addressed with topical cannabis products that act locally without systemic psychoactive effects.
What the Research Shows
The National Academies of Sciences, Engineering, and Medicine issued a landmark 2017 report, The Health Effects of Cannabis and Cannabinoids, which reviewed more than 10,000 scientific studies. Its conclusion on pain was the strongest of any condition reviewed: "substantial evidence that cannabis is an effective treatment for chronic pain in adults." This is a higher evidence standard than the report applied to most other conditions.
Since then, the evidence base has continued to grow. Multiple observational studies and clinical trials have documented:
- Significant reductions in pain severity scores (NRS/VAS scales) among chronic pain patients using medical cannabis
- Opioid-sparing effects: Patients on prescription opioids consistently report dose reductions after beginning medical cannabis; several population-level studies have found associations between medical cannabis access and reduced opioid prescribing and overdose deaths at the state level
- Improvements in sleep quality, physical function, and quality of life in chronic pain patients
One important caveat: most of the evidence is observational or from open-label trials. Conducting double-blind RCTs on cannabis is methodologically challenging (blinding is difficult; federal Schedule I status limits research funding). The evidence is robust but not drawn exclusively from gold-standard RCT designs.
What to Bring to Your PremierMD Evaluation for Chronic Pain
Your evaluation is a clinical conversation about your pain. The more specific and documented your history, the more useful the clinical guidance you receive.
Bring:
- Records showing your chronic pain diagnosis — chart notes, imaging reports (MRI, X-ray), specialist consultation notes, pain management records
- Your complete medication list — especially any current or prior opioid prescriptions, NSAIDs, nerve pain medications (gabapentin, pregabalin), or muscle relaxants. Cannabis has interactions with opioids and benzodiazepines that your provider needs to assess.
- A description of what you have tried and what has worked or not worked: physical therapy, injections, surgery, prior medications, and outcomes
- Notes on how your pain affects your daily function: sleep, mobility, work capacity, activities you have had to give up
Your PremierMD provider — Dr. Boguslavsky or one of the practice's board-certified NPs or PAs — uses this history to guide which cannabinoid profiles, delivery methods, and dosing approaches are most appropriate for your specific pain presentation.
Cannabis and the Opioid Question
Many chronic pain patients at PremierMD are either on opioid medications or have been on them in the past. This is one of the most clinically significant aspects of the cannabis-for-chronic-pain conversation.
Medical cannabis is not a substitute for opioids in cases of severe pain, and your provider will not ask you to abruptly discontinue any medications. What the clinical evidence suggests is that cannabis can serve as an adjunct that allows some patients to achieve adequate pain control at lower opioid doses. The decision to adjust opioid dosing — if it occurs at all — happens over time, with your provider's guidance, and in coordination with your prescribing physician.
New Jersey specifically added opioid use disorder as a qualifying condition to the NJMCP in recognition of cannabis's potential role in reducing opioid dependence. If opioid dependence is part of your pain picture, discuss it openly at your evaluation.
Insurance Coverage for Chronic Pain Patients
The physician evaluation at PremierMD is billed to your insurance as a standard outpatient visit. Medicare, Medicaid, and most commercial insurance plans are accepted.
For most patients with chronic pain who are on Medicare (many are older adults managing degenerative conditions), the evaluation costs a standard copay after your deductible — typically $20–$40 for Medicare without supplemental coverage, $0 with Medigap or Medicaid as secondary.
Full insurance detail: Does Insurance Cover a Medical Marijuana Evaluation in NJ?
Frequently Asked Questions: Cannabis and Chronic Pain in NJ
Does chronic pain always qualify, or do I need a specific type?
Chronic pain as listed in the NJ program includes a broad range of underlying causes — musculoskeletal, neuropathic, inflammatory, post-surgical, and others. A documented diagnosis of chronic pain by any licensed physician is the requirement. Your provider at PremierMD will assess the documentation and confirm it qualifies.
Can I use cannabis for acute (short-term) pain?
Short-term or acute pain is not a qualifying condition under the NJ program. The qualifying condition is chronic pain — typically defined as pain persisting for three months or more. Your provider will assess your history to confirm it meets the chronic criteria.
Will I have to give up my other pain medications?
No. The evaluation does not require you to stop any medications. Cannabis is typically introduced alongside existing treatment, not as a replacement. Any adjustments to other medications happen at your provider's clinical guidance and over time.
What cannabis products are typically used for chronic pain?
This is a question for your specific evaluation — the right answer depends on your pain type, current medications, and tolerance. Generally: oral (edible/sublingual) products provide longer-duration relief appropriate for chronic conditions; inhaled products have faster onset for acute breakthrough pain; topicals address localized pain without systemic effects. Your PremierMD provider guides this decision.
How long does it take to feel the effect of medical cannabis on pain?
Onset and effect time vary significantly by product type: inhaled (2–15 minutes, duration 2–3 hours), sublingual/oral tincture (15–45 minutes, duration 4–6 hours), edible (30–120 minutes, duration 4–8 hours). Finding the right product, dose, and timing for your specific pain pattern is part of the clinical guidance your provider offers.
Will my dispensary pharmacist know what to recommend?
Dispensary pharmacists are trained to work with patients managing specific conditions. The guidance your PremierMD provider gives you — which cannabinoid profiles to look for, which delivery methods are appropriate for your pain type — is what you bring to that dispensary conversation.
Get Evaluated at PremierMD
Check your eligibility or register as a patient to schedule your evaluation — in-person or telehealth.
